Breaking News, Collaborations & Alliances

BioVersys, GSK Expand Strategic TB Collaboration

Aims to accelerate clinical development of alpibectir for the treatment of tuberculosis.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

BioVersys AG, a clinical stage biopharmaceutical company developing novel antibacterial products for multi-drug resistant (MDR) bacteria, expanded its strategic collaboration with GSK plc to accelerate the clinical development of alpibectir (BVL-GSK098) for the treatment of tuberculosis (TB).   Alpibectir, a small molecule acting through a novel mode of action, was developed in a public-private collaboration with GSK, Pasteur Institute Lille and the University of Lille and is currently being e...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters